Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Non-Current Liabilities (2021 - 2024)

Historic Total Non-Current Liabilities for Aligos Therapeutics (ALGS) over the last 4 years, with Q4 2024 value amounting to $26.7 million.

  • Aligos Therapeutics' Total Non-Current Liabilities fell 1617.22% to $26.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $26.7 million, marking a year-over-year decrease of 1617.22%. This contributed to the annual value of $26.7 million for FY2024, which is 1617.22% down from last year.
  • According to the latest figures from Q4 2024, Aligos Therapeutics' Total Non-Current Liabilities is $26.7 million, which was down 1617.22% from $26.7 million recorded in Q3 2024.
  • Aligos Therapeutics' 5-year Total Non-Current Liabilities high stood at $57.4 million for Q1 2022, and its period low was $26.1 million during Q1 2024.
  • Over the past 4 years, Aligos Therapeutics' median Total Non-Current Liabilities value was $40.5 million (recorded in 2021), while the average stood at $38.7 million.
  • Per our database at Business Quant, Aligos Therapeutics' Total Non-Current Liabilities surged by 4710.78% in 2022 and then plummeted by 1617.22% in 2024.
  • Quarter analysis of 4 years shows Aligos Therapeutics' Total Non-Current Liabilities stood at $50.5 million in 2021, then dropped by 16.99% to $41.9 million in 2022, then fell by 24.02% to $31.9 million in 2023, then dropped by 16.17% to $26.7 million in 2024.
  • Its Total Non-Current Liabilities stands at $26.7 million for Q4 2024, versus $26.7 million for Q3 2024 and $30.1 million for Q2 2024.